Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Hungary

Marie Skłodowska-Curie Action · Running

NeuroblastORG Developing neural crest organoids with inducible neuroblastoma to model chemoresistance in MYCN amplification related high-risk cases

Coordinator
Hun-Ren Termeszettudomanyi Kutatokozpont, Hungary
Runs
1 March 2023 to 28 February 2025
Status
Running
EU funding
€158k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101090302

What the project is doing

In the project's own words, from its summary on CORDIS.

Neuroblastoma (NB) is the most common cancer in infants and the 3rd most common cancer in children. According to the WHO 90% of NBs occur in children younger than 5 years old and 15% of all pediatric cancer related death are due to NB. Approximately 20% of NB cases are characterized by the amplification of the MYCN gene, which is linked to more aggressive tumors and poor prognosis (high-risk NB). Despite recent treatment advances, relapsing high-risk NB often leads to death.

Understanding mechanisms of therapy resistance can help to develop more effective treatment protocols. However, investigation of acquired resistance upon chemotherapy is largely limited by the number of patients with high-risk NB and the availability of adequate model systems. Mice models of NB are often used, however species specific differences in sympathoblast development might result in misleading findings. Sympathoblast are the fetal counterparts of NB cancer cells and they are derived from the neural crest (NC).

The overall aim of the NeuroblastORG project is to establish a human organoid model of the NC lineage, which can recapitulate human specific embryonic developmental stages, while also giving rise to sympathoblast-like NB cells, in addition to healthy sympathoadrenergic lineage derivatives (NB organoid). To reach this aim, human induced pluripotent stem cell lines will be genetically modified to overexpress the MYCN gene under the control of an NC-specific promoter, but only in a subset of NC cells within the organoids.

Relevance of the established model will be validated by comparing gene expression signatures between NB organoids and human NB patient tumour samples. The NB organoid model system will provide a platform to simulate treatment of NB cells with NB-therapy relevant agents and monitor the effect of the applied treatment, allowing the investigation of human NB-specific chemoresistance acquisition in MYCN amplification related high-risk cases.

Topics

Who is involved

OrganisationCityCountryRole
Hun-Ren Termeszettudomanyi KutatokozpontBudapestHungaryCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI